Genetic insights inspire a fresh approach to restoring cellular health in Parkinson's

Amsterdam based biotech company Scenic Biotech has partnered with The Michael J. Fox Foundation for Parkinson’s Research to investigate a new treatment approach that aims to protect brain cells by repairing their internal recycling systems. The collaboration sees Scenic Biotech join the LRRK2 Investigative Therapeutics Exchange program, which is an international initiative designed to speed up the evaluation of promising scientific strategies. By combining resources, researchers plan to test how improving the health of lysosomes, which act as the waste disposal system within our cells, might offer a way to slow down or alter the progression of Parkinson's. Every cell in our body has these built in recycling centers. In a healthy cell, lysosomes break down and clear away old proteins and cellular debris to keep everything running smoothly. In Parkinson's, these waste disposal systems can slow down or fail. When lysosomes stop working efficiently, cellular trash builds up inside the brain cells, leading to damage and inflammation. This biological breakdown is widely considered a core driver of how the condition progresses over time. Scenic Biotech has developed a new class of drugs known as PLA2G15 inhibitors. These are brain penetrant small molecules, meaning they are designed to be tiny enough to cross the protective blood brain barrier and enter the brain where they are needed most. Inside the cells, these compounds work by blocking a specific enzyme that normally breaks down a protective lipid, or fat, known as BMP. By stopping this breakdown, the drug boosts the levels of this helpful lipid, giving the lysosomes a power boost and restoring their ability to clear away cellular waste. This specific biological pathway is closely linked to genetic forms of Parkinson's. The protective lipid boosted by the drug helps regulate another vital enzyme called GCase, which is frequently impaired in people who carry mutations in the GBA1 or LRRK2 genes. The initial phase of this project will take place in Scotland at the University of Dundee, where scientists will test the new compounds in advanced laboratory models to see exactly how well they protect cells and improve waste disposal. If these tests are successful, the data gathered will be used to design and accelerate future clinical trials in humans, with the ultimate goal of developing a treatment that moves beyond just managing symptoms to directly targeting the underlying biology of Parkinson's.